利拉鲁肽对初发2型糖尿病伴肥胖患者的疗效及微炎症状态的影响研究

Effect of liraglutide on the efficacy and microinflammation of Type 2 Diabetes with obesity

目的研究利拉鲁肽对初发2型糖尿病伴肥胖患者的疗效及微炎症状态的影响。方法选择本院2017年5月至2018年5月收治的72例初发2型糖尿病伴肥胖患者作为研究对象,依据抽签法分为对照组(n=36)和实验组(n=36),对照组予以二甲双胍治疗,口服给药,每次1.0 g,每天2次,实验组予以利拉鲁肽治疗,皮下注射给药,每次0.6 mg,每天1次;1周后若患者未出现其他不良反应,则将药物剂量增至1.2 mg,每天1次,对于治疗期间发生低血糖的患者,需要适当减少给药剂量。两组均连续进行3个月的治疗,比较治疗后机体指标及微炎症状态改善情况的差异。结果两组治疗后FBG(空腹血糖)、HbA1c(糖化血红蛋白)、BMI(体重指数)进行比较,实验组均显著低于对照组,组间存在统计学意义(P<0.05);实验组治疗后ASAA(急性时相血清淀粉样蛋白A)、IL-6(白介素-6)、TNF-α(肿瘤坏死因子α)均比对照组显著降低,组间差异有统计学意义(P<0.05)。结论初发2型糖尿病伴肥胖患者采用利拉鲁肽治疗,有利于显著降低体重指数,改善血糖水平和缓解微炎症状态,可将其作为理想治疗药物在临床中进行深入推广和普及。

Objective To study the effect of liraglutide on the efficacy and micro-inflammation of newly diagnosed type 2 diabetic patients with obesity. Methods Seventy-two newly diagnosed type 2 diabetic obese patients admitted to our hospital from May 2017 to May 2018 were selected as the study subjects. They were divided into control group(n=36) and test group(n=36) according to the lottery method. The group was treated with metformin and orally administered, 1.0 g per time, twice a day. The test group was treated with liraglutide and subcutaneously, 0.6 mg per time, once a day;if there was no other adverse disease after 1 week. In response, the dose of the drug was increased to 1.2 mg once daily, and for those patients who experienced hypoglycemia during treatment, the dosage should be appropriately reduced. Both groups were consecutively treated for 3 months,and the differences in body indicators and micro-inflammatory status after treatment were compared. Results After treatment, the FBG(fasting plasma glucose), HbA1 c(glycosylated hemoglobin), and BMI(body mass) were significantly lower in the experimental group than in the control group.There was a statistically significant difference between the two groups(P<0.05);After the ASAA(acute phase serum amyloid A), IL-6(interleukin-6), TNF-α(tumor necrosis factor α) were significantly lower than the control group, the difference between the groups was significant(P<0.05).Conclusion The use of liraglutide in patients with newly diagnosed type 2 diabetes associated with obesity is beneficial to significantly reduce body mass index, improve blood glucose level and relieving micro-inflammation status. It can be used as an ideal therapeutic drug for further promotion and popularization in clinical practice.